Insights – nineonecapital.in

Further Work on Venus Remedies: The Etimicin Opportunity
Source: Nine One Capital Published on 2025-12-06
Quarterly Update: Process, Survival & the Path Ahead
Source: Nine One Capital Published on 2025-11-30
The Trouble With Buying Great Narratives at Great Prices
Source: Nine One Capital Published on 2025-11-26
CWD: Hyper-Growth Phase Begins
Source: Nine One Capital Published on 2025-11-16
Venues Remedies Q2 FY26 Results
Source: Nine One Capital Published on 2025-11-10
When One Fraud Raised Questions on 15 Other Listed Companies
Source: Nine One Capital Published on 2025-11-08
Rare Earths: Positioning Early for the Next Strategic Mining Wave
Source: Nine One Capital Published on 2025-10-26
Eimco Elecon: A Clean Slate with Optionality Ahead
Source: Nine One Capital Published on 2025-10-14
How to Analyse a 100 PE Stock
Source: Nine One Capital Published on 2025-09-24
AI Can Read, It Can’t Infer
Source: Nine One Capital Published on 2025-09-17
Preparing, Not Predicting
Source: Nine One Capital Published on 2025-09-02
Supreme Court’s Stray Dog Ruling: A ₹20 Billion Tailwind for Animal Health Stocks?
Source: Nine One Capital Published on 2025-08-25
What the Indices Don’t Tell You
Source: Nine One Capital Published on 2025-08-15
Cooling Off to Heat Up: Why We’re Studying the AC Sector Now
Source: Nine One Capital Published on 2025-08-10
Unlisted Doesn’t Mean Uncertain: Our Playbook for Investing in Unlisted Companies
Source: Nine One Capital Published on 2025-08-05